Stock Ratings / Health Care / ZYBT / financials

OSTX (42) RNXT (31) FBIO (39) MNOV (30) ⌘ Pro Terminal →

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.30 -9.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.28

Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $67.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZYBT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZYBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.30 (-9.09% 1D, market cap $67.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZYBT ranks #531 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZYBT compare to OSTX and RNXT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and RNXT (RenovoRx Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $67.2M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZYBT?

▼

Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.28 (-1.83%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 10.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZYBT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY ZYBT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 10.6% FCF Margin ($1.8M FCF) & 20.5% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (20% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.73-19.1% Next Q

Q2 (-2Q)

Grade D$1.40+7.1% Next Q

Q3 (-1Q)

Grade D$1.50-13.3% Next Q

Current

Grade D-$1.30-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZYBT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZYBT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.48) and Max Pain ($1.37) forces dealer call-delta covering toward $8.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZYBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZYBT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ZYBT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$1.8M (10.6% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $25.5M

FY25

Rev $16.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$16.6M	20.5%	-60.6%	-$10.0M	$1.8M	-22.3%
FY 2024	$25.5M	49%	8.8%	$1.6M	$3.8M	4.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZYBT)

✓Walkthrough of ZYBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZYBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.30%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.17H $1.40L $1.17C $1.30VOL 122.9K

RES: $3.19SUP: $1.08SMA50: $1.48SMA200: $1.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZYBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZYBT Butterfly Map → + Track ZYBT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -34.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZYBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZYBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZYBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZYBT)

Health Care Rank #531 of 1016 ⚔️ OSTX vs ZYBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZYBT vs. OSTX, RNXT, FBIO, MNOV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) ranks #531 by composite RQD confidence (40/100, grade D-) and #710 by equity capitalization ($67.8M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ZYBT at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZYBT ACTIVE Zhengye Biotechnology Holding Limited (Class A)	D-	40/100	—	20.5%	-22.3%	-9.09%	$67.8M	Benchmark Subject
OSTX OS Therapies Incorporated	D-	42/100	—	—	-35.0%	-4.61%	$67.6M	/ostx-vs-zybt →
RNXT RenovoRx Inc.	E	31/100	—	70.9%	-35.0%	-10.74%	$67.2M	/rnxt-vs-zybt →
FBIO Fortress Biotech Inc.	D-	39/100	—	66.9%	-35.0%	-4.00%	$66.7M	/fbio-vs-zybt →
MNOV Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	/mnov-vs-zybt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001975641

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zhengye Biotechnology Holding Limited (Class A) (ZYBT) reported GAAP revenue of $16.6M (-34.8% vs. FY2024 revenue of $25.5M ) , GAAP net income of -$10.0M, operating cash flow of $1.9M, and free cash flow of $1.8M (-53.0% YoY). On the balance sheet, ZYBT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 1.90, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.6M	-$10.0M	$1.9M	$1.8M	$62.4M	—
FY2024 (FY)	2024-12-31	$25.5M	$1.6M	$5.6M	$3.8M	$67.6M	$658.0K

3. ZYBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZYBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZYBT compare to OSTX and RNXT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZYBT?

Where is ZYBT trading relative to its 50-day, 200-day, and 52-week technical levels?

ZYBT last traded at $1.30 (-9.09% on volume of 122,945 shares), positioning the stock -12.16% below its 50-day simple moving average ($1.48) and +12.07% above its 200-day simple moving average ($1.16). Across its 52-week range of $0.62 to $8.01, ZYBT sits at the 9.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.14 to $1.46).

ZYBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Zhengye Biotechnology Holding Limited (Class A) (ZYBT)?

In FY 2025 (10-K), ZYBT converted $16.6M of revenue into a 20.5% gross margin, 0% operating margin, and $1.8M in free cash flow (10.6% FCF margin).

Direct Sub-Reports: ZYBT RQD Cockpit ZYBT 12M Forecast ZYBT Earnings & Move ZYBT Dividends & DRIP ZYBT Insiders & 13F ZYBT Whale Options ZYBT Profit Sankey ZYBT News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZYBT — Zhengye Biotechnology Holding Limited (Class A): What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a composite score of 40/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $1.30 (-9.09%). Fundamental cash generation scores 10/20 (ROIC -22.3%, FCF yield 2.61%), institutional 13F whale accumulation scores 8/20, insider conviction scores 7/20, macro regime alignment scores 8/20 (Beta 1.00), and forensic balance-sheet protection scores 7/20 (Altman Z-Score 1.90, Piotroski F-Score 4/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $0.62 – $8.01.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ZYBT is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin 20.5%), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

ZYBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zhengye Biotechnology Holding Limited (Class A) (ZYBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZYBT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 103d ago

Zhengye Biotechnology Says No Material Events Behind Unusual Trading Activity (NASDAQ:ZYBT)

The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NA

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 150d ago

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 210d ago

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 104d ago

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 88d ago

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 187d ago

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Yahoo Finance coverage on ZYBT stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 265d ago

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,

Read Full Source ↗

🟡 MARKET WIRE TradingView • 7d ago

Zhengye Biotechnology Holding Limited Estimates – NASDAQ:ZYBT

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5QWEdnZ3VYSGZNRUVROVI2OVVSbVJVVXJjU25sa0toM3FTU0xSQUtSelE4bkkxdHh3UlRfVVhpbldoT1AwRzFPRndhbVFWa3hBUnZGX3FaY3F0dFZfeHpvNW9adXJGSGM3NE9veDNfelktSmZGRGZaTw?oc=5

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZYBT Bull vs. Bear Conversation Board — What's Your Call at $1.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZYBT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.14 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ZYBT (D- • RQD 40/100) a Buy at $1.30?

Welcome to the ZYBT (Zhengye Biotechnology Holding Limited (Class A)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.09 (-16.2%)

Spot @ $1.30

Pump the brakes on ZYBT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ZYBT, but look at what you are paying: current EV/EBITDA multiples with 20.5% gross margins. Unless Zhengye Biotechnology Holding Limited (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.55 (+19.2%)

Spot @ $1.30

ZYBT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ZYBT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.30 (52-wk range $0.62 - $8.01), any beat on forward guidance forces shorts and underweight funds to chase.